Entera Bio Ltd Stock Price, News & Analysis

Entera Bio Ltd. (NASDAQ: ENTX) announced the completion of enrollment in its Phase 2 clinical trial for EB613, an oral treatment for osteoporosis. This study involves 161 postmenopausal women and aims to evaluate the drug's effect on bone mineral density (BMD). Interim results showed a placebo-adjusted BMD increase of 2.15% in the highest dose group. Full biomarker data is expected in Q1 2021, with final results due in Q2 2021. Entera has $7.1 million in cash, sufficient to support operations into the second quarter of 2021, despite challenges from COVID-19.

Entera Bio Ltd. (NASDAQ: ENTX) announced a virtual presentation at the H.C. Wainwright Annual Israel Conference on November 12, 2020 at 8:00 a.m. ET. The event will showcase its advancements in orally delivered large molecule therapeutics, targeting unmet medical needs in healthcare.

Entera’s proprietary technology addresses challenges in drug absorption, focusing on its lead candidates, EB613 for osteoporosis and EB612 for hypoparathyroidism, currently in Phase 2 clinical development.

Entera Bio Ltd. (NASDAQ: ENTX) will participate virtually in the H.C. Wainwright Global Investment Conference on September 15, 2020, at 3:00 p.m. EDT. Investors can access a live webcast of the presentation via the company’s website, with a replay available for 45 days after. Entera specializes in the development of orally delivered large molecule therapeutics for conditions like osteoporosis and hypoparathyroidism, leveraging proprietary technology to improve absorption and delivery. The company's candidates EB613 and EB612 are currently in Phase 2 clinical trials.

Entera Bio Ltd. (NASDAQ: ENTX) announced promising interim data from its Phase 2 clinical trial of EB613, an oral treatment for osteoporosis. The 6-month results demonstrated a mean placebo-adjusted increase of 2.15% in lumbar spine bone mineral density (BMD) for the 1.5 mg treatment group. With 131 subjects currently enrolled, the company expects to complete enrollment by Q3 2020. Financially, Entera reported revenues of $94,000 and an operating loss of $6.4 million for the first half of 2020, an increase from the previous year. Cash reserves stood at $9.8 million, sufficient to cover operations into Q2 2021.

Entera Bio Ltd. (NASDAQ: ENTX) will report its business and financial results for Q2 2020 on August 20, 2020, before U.S. markets open. A conference call is scheduled for 8:30 a.m. EDT on the same day, featuring management's discussion followed by a Q&A session. Participants can dial (855) 547-3865 (US) or (409) 217-8787 (international) with the ID '5243229'. Entera focuses on developing orally delivered large molecule therapeutics, including EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 trials.

Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the BTIG Biotechnology Conference on August 10, 2020, at 12:30 p.m. EDT. The event will be available via a live webcast on the company's Investor Relations page. A replay will be accessible for 45 days post-presentation.

Entera specializes in orally delivered macromolecule therapeutics addressing significant medical needs, particularly for patients who struggle with injectable therapies. Their leading candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 clinical development.

Entera Bio Ltd. (NASDAQ: ENTX) reported significant progress in its Phase 2 clinical trial of EB613 for osteoporosis, with interim data showing statistically significant increases in the P1NP biomarker after one month of treatment. The 1.5 mg dose demonstrated notable improvement over placebo. The company plans to follow patients for six months to analyze bone mineral density data and explore higher doses for potential Phase 3 trials. Financially, Entera reported Q1 2020 revenue of $42,000 with a net loss of $(2.9) million, and cash reserves of $13.3 million, projected to last until mid-2021.

Entera Bio Ltd. (NASDAQ: ENTX) has announced it will release interim biomarker data from its Phase 2 osteoporosis clinical trial of EB613 and financial results for Q1 2020 on May 21, 2020, before the market opens. The first half of data will cover 50% of enrolled patients. A conference call will be held on the same day at 8:30 a.m. EDT to discuss findings and results, with a Q&A session to follow. Entera Bio focuses on developing orally delivered large molecule therapeutics, addressing unmet medical needs.